169 related articles for article (PubMed ID: 32087434)
1. A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
Alexander M; Pavlakis N; John T; O'Connell R; Kao S; Hughes BGM; Lee A; Hayes SA; Howell VM; Clarke SJ; Millward M; Burbury K; Solomon B; Itchins M
Lung Cancer; 2020 Apr; 142():34-40. PubMed ID: 32087434
[TBL] [Abstract][Full Text] [Related]
2. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
Chiari R; Ricciuti B; Landi L; Morelli AM; Delmonte A; Spitaleri G; Cortinovis DL; Lamberti G; Facchinetti F; Pilotto S; Verusio C; Chella A; Bonanno L; Galetta D; Cappuzzo F
Clin Lung Cancer; 2020 Jan; 21(1):15-20. PubMed ID: 31607443
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
4. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
Liu C; Yu H; Chang J; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Wang J
Target Oncol; 2019 Jun; 14(3):315-323. PubMed ID: 30976989
[TBL] [Abstract][Full Text] [Related]
6. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
[TBL] [Abstract][Full Text] [Related]
7. ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.
Lee A; Howell VM; Itchins M; Wheeler HR; Pavlakis N
Clin Lung Cancer; 2018 Sep; 19(5):457-459. PubMed ID: 29945753
[No Abstract] [Full Text] [Related]
8. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
Shaw AT; Riely GJ; Bang YJ; Kim DW; Camidge DR; Solomon BJ; Varella-Garcia M; Iafrate AJ; Shapiro GI; Usari T; Wang SC; Wilner KD; Clark JW; Ou SI
Ann Oncol; 2019 Jul; 30(7):1121-1126. PubMed ID: 30980071
[TBL] [Abstract][Full Text] [Related]
9. Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.
Wang HY; Wu SG; Lin YT; Chen CY; Shih JY
ESMO Open; 2022 Dec; 7(6):100742. PubMed ID: 36493600
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
Park E; Choi YL; Ahn MJ; Han J
Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
Zhu VW; Zhao JJ; Gao Y; Syn NL; Zhang SS; Ou SI; Bauer KA; Nagasaka M
Lung Cancer; 2021 Jul; 157():147-155. PubMed ID: 34049720
[TBL] [Abstract][Full Text] [Related]
13. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.
Muñoz-Unceta N; Zugazagoitia J; Manzano A; Jiménez-Aguilar E; Olmedo ME; Cacho JD; Oliveira J; Dómine M; Ortega-Morán L; Aguado C; Luna AM; Fernández L; Pérez J; Font C; Salvador C; Corral J; Benítez G; Ros S; Biosca M; Calvo V; Martínez J; Sánchez-Cánovas M; López R; Sereno M; Mielgo X; Aparisi F; Carmona M; Carrión R; Ponce-Aix S; Soares M; Martínez-Salas I; García-Morillo M; Juan-Vidal O; Blasco A; Muñoz AJ; Paz-Ares L;
Eur J Cancer; 2020 Dec; 141():193-198. PubMed ID: 33166862
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
15. ROS1 copy number alterations are frequent in non-small cell lung cancer.
Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
[TBL] [Abstract][Full Text] [Related]
17. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
[TBL] [Abstract][Full Text] [Related]
18. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT
Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389
[TBL] [Abstract][Full Text] [Related]
19. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
20. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
